ModifiedUnitedHealthcarePolicy CS129OH.D

Vagus and External Trigeminal Nerve Stimulation (for Ohio Only)

Ohio-only UnitedHealthcare medical policy governing coverage and medical necessity determinations for implantable and noninvasive vagus nerve stimulation (VNS/tVNS) and external trigeminal nerve stimulation (TNS/eTNS) devices for members in Ohio.

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation (for Ohio Only)

Policy CodePolicy CS129OH.D

Change TypeDocumentation and cross-reference updates

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain and retain complete medical record documentation to demonstrate medical necessity and check federal, state, and contractual benefit requirements before requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

Added language clarifying that benefit coverage is determined by federal, state, or contractual requirements and that medical records documentation may be required to assess whether the member meets clinical criteria for coverage.

Updated related policy link for Transcranial Magnetic Stimulation for Treating Physical Health Conditions (for Ohio Only).

Ohio-onlyState applicability

YesFDA-cleared devices referenced

NumerousUnproven/not medically necessary indications

Insufficient

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

nVNS evidence overall

IncludedCodes listed

Coverage and Medical Necessity Criteria

Covered indications per InterQual reference

See InterQual® clinical criteria for specific coverage definitions, clinical thresholds, and documentation requirements.

Not Medically Necessary / Unproven Indications

Not medically necessary / Unproven indications

These items reflect insufficiency of evidence and are consistent with InterQual guidance and internal medical policy review.

Transcutaneous (non‑implantable) VNS — Evidence Insufficiency Summary

Overall stance — Insufficient evidence

Insufficiency summary: small trials, inconsistent results between subtypes (e.g., episodic vs chronic cluster headache), sham devices with unintended stimulation, and adherence issues in trials.

Cluster Headache — mixed evidence by subtype

Cluster headache — mixed evidence by subtype

NICE recommends treatment continuation only for people whose symptoms reduce in the first 3 months; this operationalizes a short trial and response assessment period.

Migraine — limited and mixed evidence

Given heterogeneity and quality limitations, use of noninvasive VNS or eTNS for migraine should be limited to cases meeting InterQual criteria or within research/special arrangements.

Providers must document adherence and trial response when requesting continuation.

gammaCore for cluster headache — trial and continuation

Operational note: lack of long‑term data — continuation should be reassessed periodically and documented in the medical record.

eTNS for migraine — acute vs preventive

Providers must document trial response and adherence if eTNS is provided; lack of clear evidence may lead to denial.

Other neurologic and non‑neurologic indications — investigational

Insufficient evidence for non‑headache indications may trigger denial.

Providers should supply detailed medical records and rationale if requesting exceptional coverage.

Prior Authorization

Provider Actions and Documentation Requirements

Providers must obtain prior authorization where required and verify device FDA clearance and model. A short, documented trial (up to 3 months) is required for nVNS devices used for cluster headache; continuation will be approved only with documented improvement. Evidence insufficiency for many indications may result in denial — especially for non‑headache uses and for implantable devices when not justified by InterQual criteria.

Check member benefits and prior authorization requirements before ordering.
Confirm device is FDA‑cleared for the intended indication and document device model and serial number in the medical record.
For gammaCore and other nVNS devices used for cluster headache, document response within first 3 months (frequency, severity, acute medication use, functional impact).
Maintain medical records documenting trial response, adherence, adverse events, and rationale for continuation.
Insufficiency of evidence for non‑headache indications may trigger denial.

Applicable Procedure and Product Codes

Applicable CPT CodesCPT

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.

Applicable HCPCS / L-codesHCPCS

A4541	Monthly supplies for use of device coded at E0733.
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve.
E0735	Noninvasive vagus nerve stimulator.
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.
E1399	Durable medical equipment, miscellaneous.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

1–10 of 13

1/2

Implantable VNS device product codesmixed

LYJ	FDA product code referenced for implantable VNS devices (informational)
MUZ	FDA product code referenced for implantable VNS devices (informational)
QPY	FDA product code referenced for implantable VNS devices (informational)

Transcutaneous VNS device product codesmixed

PKR	FDA product code referenced for transcutaneous (non-implantable) VNS devices (informational)
QAK	FDA product code referenced for transcutaneous (non-implantable) VNS devices (informational)

External/Transcutaneous Trigeminal Nerve Stimulation device product codesmixed

PCC	FDA product code referenced for external/transcutaneous trigeminal nerve stimulation devices (informational)
QGL	FDA product code referenced for external/transcutaneous trigeminal nerve stimulation devices (informational)

Coding referencesmixed

No codes listed

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior authorization applies to listed codes

Prior authorization and medical necessity review apply to the procedure, supply, and HCPCS/L codes listed in this policy when services are requested for Ohio members.

CPT codes: 61885, 61886, 64553, 64568, 64570.
HCPCS/L codes: A4541, E0733, E0735, E0770, E1399, L8679–L8688.

Prior Authorization

Device FDA clearance should be referenced in prior authorization

Some devices discussed in this policy have FDA marketing approvals/clearances; prior authorization requests should reference device‑specific clearances when applicable and may be required per payer policy.

Refer to FDA product codes LYJ/MUZ/QPY for implantable VNS, PKR/QAK for transcutaneous VNS, and PCC/QGL for eTNS when locating marketing clearance information.

Note

Background and Scope

Vagus nerve stimulation (VNS) delivers electrical impulses to the brain via the vagus nerve. Implantable VNS systems use a surgically implanted pulse generator and leads connected to the cervical vagus nerve, while noninvasive approaches—such as transcutaneous VNS (tVNS) and external/transcutaneous trigeminal nerve stimulation (eTNS)—use surface electrodes targeting auricular, cervical vagal branches, or supraorbital/trigeminal branches. Proposed mechanisms include modulation of neurotransmitter release and alteration of central neural networks. Evidence quality across indications varies; many noninvasive applications remain investigational and require further research to establish long‑term safety and effectiveness.

Device and Clinical Definitions

Implantable VNS definition

TermImplantable VNS

DefinitionSurgically implanted generator and leads delivering electrical impulses to the cervical vagus nerve to modulate brain activity; typically implanted in the chest with leads wrapped around the vagus nerve in the carotid sheath.

Typical indications (documented)Epilepsy and treatment‑resistant depression (paralleling implantable VNS use); other indications are investigational or unproven per policy.

Transcutaneous VNS (tVNS) definition

TermTranscutaneous VNS (tVNS)

DefinitionNoninvasive delivery of electrical impulses via surface electrodes targeting auricular (ABVN) or cervical branches of the vagus nerve (example device: gammaCore), intended to stimulate vagal pathways without surgical implantation.

Policy Revision History

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation (for Ohio Only)

Policy CodePolicy CS129OH.D

Change TypeDocumentation and cross-reference updates

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

Check federal/state/contractual benefit requirements

Before applying this policy, verify federal, state (OAC), or contractual benefit requirements because they govern coverage; UnitedHealthcare may require InterQual or other approved criteria when determining medical necessity.

Documentation Required

Document baseline and short‑trial response (objective measures)

When coverage is being considered, document a short therapeutic trial baseline and objective evidence of symptomatic reduction (for example, baseline attack frequency and reduction within a short trial period) to justify ongoing therapy.

Policy indicates continued gammaCore therapy should only continue for people whose symptoms reduce within the first 3 months.
Document baseline attack frequency and objective evidence of symptomatic reduction during the trial period.

Step Therapy

Document prior pharmacotherapy trials per AHS guidance

Document prior pharmacotherapy trials, intolerance, or contraindications: AHS suggests neuromodulation may be considered for individuals who have failed, cannot tolerate, or have contraindications to pharmacologic therapy.

Record medications tried, durations, responses, and reasons for discontinuation or intolerance to support candidate status for neuromodulation.

Step Therapy

Consider pharmacotherapy before neuromodulation (stepwise care)

Follow a stepwise treatment approach: consider standard pharmacologic and behavioral therapies before neuromodulation and document failure or intolerance to those therapies when seeking neuromodulation.

Providers should document that pharmacotherapy was tried and either failed, was not tolerated, or was contraindicated prior to neuromodulation request.

Note

Clinical criteria sources: InterQual primary; UHC policies may apply

UnitedHealthcare uses InterQual for primary medical/surgical criteria; if InterQual does not have applicable criteria, UnitedHealthcare medical policies, coverage determination guidelines, or utilization review guidelines may be applied.

Documentation Required

Required medical record documentation

Maintain complete medical record documentation to support medical necessity, including relevant history, physical exam findings, and pertinent diagnostic test/procedure results; documentation must be legible, retained, and available upon request.

Include clinical history, exam findings, diagnostic test results, and any relevant specialist consultations.
Make records available upon request for medical necessity review.

Documentation Required

Document trial response within first 3 months (NICE recommendation)

Document objective symptom reduction during the first 3 months of therapy when applicable; NICE recommends continuing treatment only for people whose symptoms reduce within this initial period.

For gammaCore in cluster headache, continue only if symptoms reduce within the first 3 months.
Record objective measures of response during months 0–3 to support continuation.

Documentation Required

Document response and governance for continuation decisions

Provide clear response documentation to support continuation decisions and governance: show clinical response within recommended trial periods and, where applicable, adherence to governance/consent/audit arrangements per guidance.

For gammaCore, document symptom reduction within trial period to justify ongoing therapy.
For eTNS acute use, document adherence to any special arrangements for governance, consent, audit, or research as recommended by NICE.

Documentation Required

Medical records may be required; federal/state/contractual precedence applies

Medical records may be requested to assess whether the member meets clinical criteria; remember that federal, state (OAC), or contractual requirements govern coverage and may supersede policy guidance.

Denial Risk

Denial risk if documentation does not support medical necessity

Coverage may be denied if medical records do not fully support the medical necessity for the requested services; ensure documentation is complete and available upon request to mitigate denial risk.

Incomplete, illegible, or missing documentation supporting history, exam, or diagnostic testing can lead to denial.
Maintain documentation of baseline symptoms, treatment trials, trial outcomes, and device‑related assessments.

Clinical contextEvaluated for acute and preventive treatment of migraine and cluster headache; evidence described as limited or insufficient for many indications.

External/Transcutaneous Trigeminal Nerve Stimulation (TNS/eTNS) definition

TermExternal/Transcutaneous Trigeminal Nerve Stimulation (TNS/eTNS)

DefinitionNoninvasive stimulation delivered through electrodes applied to the forehead to stimulate supraorbital/infraorbital branches of the trigeminal nerve (examples: Monarch eTNS, Cefaly).

Regulatory noteThe FDA has cleared devices for eTNS (product codes PCC, QGL); clinical benefit evidence is described as low quality and uncertain durability.

episodic vs chronic cluster headache distinction

DistinctionEpisodic cluster headache (eCH) vs chronic cluster headache (cCH)

Clinical differenceTrials and meta-analyses report nVNS is superior to sham for acute treatment in episodic cluster headache but not in chronic cluster headache.

ImplicationMany studies stratify results by subtype; efficacy seen in eCH does not reliably generalize to cCH and long‑term outcomes remain uncertain.

nVNS sham device issue

IssuenVNS sham device issue

DescriptionSome sham devices used in trials inadvertently produced levels of vagal stimulation, confounding comparisons and reducing ability to detect treatment effects.

ConsequenceSham activity and other design limitations (e.g., bilateral stimulation, adherence problems) have been cited as key limitations in interpreting trial results for migraine and prevention studies.

gammaCore / nVNS device description

DevicegammaCore (nVNS)

DescriptionA handheld, noninvasive transcutaneous vagus nerve stimulation device intended to deliver stimulation to cervical vagal branches; studied for acute treatment of episodic cluster headache and evaluated in migraine prevention trials (gammaCore).

GuidanceNICE and evidence summaries note gammaCore reduces frequency/intensity in some patients with cluster headache but treatment should continue only if symptoms reduce within the first 3 months.

eTNS / external trigeminal nerve stimulation (Cefaly, etc.)

DevicesCefaly, Monarch (eTNS examples)

DefinitioneTNS refers to transcutaneous stimulation of supraorbital/trigeminal branches via a forehead electrode system (Cefaly, Monarch) evaluated for acute and preventive migraine and other indications.

Evidence summarySystematic reviews report pain reduction vs sham but overall evidence quality is low and long‑term benefits, optimal protocols, and generalizability remain uncertain.

non-invasive vagus nerve stimulation (nVNS) definition

TermNon‑invasive vagus nerve stimulation (nVNS)

DefinitionTranscutaneous or external stimulation of vagal nerve branches (cervical or auricular) delivered without implantation, used for acute or preventive treatment in conditions such as migraine and cluster headache.

Clinical noteEvidence across trials is heterogeneous; some studies show benefit for certain endpoints or subgroups, but overall quality is limited and further robust RCTs are needed.

paired VNS (Vivistim/VNS-REHAB) definition

TermPaired VNS (Vivistim / VNS‑REHAB)

DefinitionInvasive or device‑based vagus nerve stimulation paired with rehabilitation therapies to improve upper limb motor function after ischemic stroke; exemplified by Vivistim/VNS‑REHAB trials assessing motor recovery when VNS is paired with rehabilitation exercises.

Evidence noteRandomized pivotal device trials (VNS‑REHAB) and ECRI assessments have evaluated paired VNS for post‑stroke upper limb function; this use is distinct from tVNS/nVNS for headache indications.